共查询到18条相似文献,搜索用时 78 毫秒
1.
以纯化得到的两条具有ACE抑制活性的肽(P1和P2)为基础,通过基质辅助激光解吸电离飞行时间质谱(MALDI TOF MS)确定P1、P2的氨基酸序列,并采用固相合成法合成,随后对它们的抑制动力学进行研究,最后用Sybyl软件分别将其与ACE进行分子对接。结果表明:P1的氨基酸序列为Gly-Asn-Pro-Trp-Met(IC50值为12.61μg/m L),为非竞争性抑制肽,抑制常数Ki,1=0.037 mmol/L;P2的氨基酸序列为Asn-Arg-Tyr-Leu-Arg(IC50值为14.68μg/m L),为竞争性抑制肽,其抑制常数Ki,2=0.020 mmol/L;P1、P2都能与ACE活性位点氨基酸残基形成氢键。P1、P2可以作为预防高血压的功能性食品,为蚕蛹蛋白的进一步开发利用提供理论基础。 相似文献
2.
应用6种商业蛋白酶水解牦牛乳酪蛋白,研究其水解产物的血管紧张素转换酶抑制活性,结合蛋白水解度及蛋白回收率的结果,蛋白酶C适用于制备牦牛乳酪蛋白源血管紧张素转换酶抑制肽。 相似文献
3.
血管紧张素转化酶(angiotensin converting enzyme,ACE)抑制剂通过抑制ACE活性能够降低血压。目前人工合成ACE抑制药物已开发并应用到降血压的治疗中,但会带来多种副作用。食源性ACE抑制肽与合成抑制剂相比因其副作用小、安全性高等特点,成为ACE抑制肽研究的热点。由于独特的生活环境与巨大的存在数量,海洋生物具有与陆地生物截然不同的化学结构及丰富的生物活性成分。海洋生物来源ACE抑制肽的研究为食源性ACE抑制肽的筛选提供了基础。本文结合海洋生物来源ACE抑制肽的作用机制及制备流程,对鱼类、软体动物、虾类、藻类及海绵、海蜇、粗刺参等不同生物来源的ACE抑制肽制备工艺进行了综述,并对海洋生物的综合开发利用进行了概括。 相似文献
4.
5.
6.
7.
本实验以脂质体作为包埋载体,研究血管紧张素转换酶(angiotensin converting enzyme,ACE)抑制肽Arg-Leu-Ser-Phe-Asn-Pro(RLSFNP)脂质体的制备工艺。以包封率为考察指标,采用单因素试验和响应面试验优化RLSFNP脂质体的制备工艺。得出最优制备条件为:大豆卵磷脂用量120.0 mg、胆固醇用量24.6 mg、RLSFNP用量15.3 mg、乙醚用量15.0 m L、磷酸盐缓冲液(p H 7.4)用量5.8 m L、探头超声时间5.2 min。在此条件下制备的脂质体平均粒径在168 nm左右,电位为-31.2 m V,实际包封率为(67.5±0.8)%,由脂质体包埋后的RLSFNP具有一定的缓释效果。 相似文献
8.
血管紧张素转化酶(angiotensin I converting enzyme,简称ACE)对于人体血压的调节有着十分重要的作用。血管紧张素转化酶抑制肽(ACEIP)是从食源性蛋白质中提取的功能性肽,有着抑制ACE的作用,从而降低人体血压,达到治疗高血压的目的。本文主要从ACE抑制肽的降压原理、来源、结构、分类及作用特点和前景展望这几方面对其进行总结阐述。 相似文献
9.
血管紧张素转化酶(angiotensin I converting enzyme,简称ACE)对于人体血压的调节有着十分重要的作用。血管紧张素转化酶抑制肽(ACEIP)是从食源性蛋白质中提取的功能性肽,有着抑制ACE的作用,从而降低人体血压,达到治疗高血压的目的。本文主要从ACE抑制肽的降压原理、来源、结构、分类及作用特点和前景展望这几方面对其进行总结阐述。 相似文献
10.
11.
Inhibitors of angiotensin I-converting enzyme (ACE) are useful in treating hypertension, and many have been derived from food products, including soybeans. Using the industrial protease PROTIN SD-NY10, we developed a processed soya milk (PSM) with enhanced ACE inhibitory activity. The ACE inhibitory activity of PSM (IC50 = 0.26 μg/ml) was greater than that of regular soya milk (IC50 = 8.75 μg/ml). Eight novel ACE inhibitory peptides were purified from PSM by reversed-phase chromatography: FFYY (IC50,1.9 μM), WHP (4.8 μM), FVP (10.1 μM), LHPGDAQR (10.3 μM), IAV (27.0 μM), VNP (32.5 μM), LEPP (100.1 μM), and WNPR (880.0 μM). The IC50 values of these peptides are comparable to those reported for other ACE inhibitory peptides derived from wheat, chicken, bonito, wine, etc. Due to the relatively low IC50 values of several peptides identified in this study, they may serve as ideal base components of food supplements for patients with hypertension. 相似文献
12.
Angiotensin I-converting enzyme (ACE) inhibitory activities in untreated koumiss and koumiss digested with ACE, pepsin, trypsinase, and chymotrypsin were compared and analyzed. Four novel ACE inhibitory peptides (PI, PK, PM, and PP) were purified using ultrafiltration and high performance liquid chromatography (HPLC). The classification study showed that these 4 peptides were of the true inhibitor type. The amino acid sequences of these peptides are YQDPRLGPTGELDPATQPIVAVHNPVIV, PKDLREN, LLLAHLL, and NHRNRMMDHVH, respectively. Their individual IC50 (50% inhibitory concentration) values were as follows: 14.53 ± 0.21 μM, 9.82 ± 0.37 μM, 5.19 ± 0.18 μM, and 13.42 ± 0.17 μM. From sequence analysis, we determined that PI was part of β-casein in mare's milk. The 3 peptides PK, PM, and PP did not correspond with any known milk protein. The results suggest that koumiss is rich in ACE inhibitory peptides, and the ACE inhibitors in koumiss are of the pro-drug type or a mixture of the pro-drug type and the true inhibitor type. These results may provide evidence about the beneficial effects of koumiss, especially on cardiovascular health. 相似文献
13.
Bovine lactic casein was hydrolysed using a combination of three enzymes, namely, subtilisin, bacillolysin, and trypsin, and the resulting preparation was coined CH-3. CH-3 showed angiotensin I-converting enzyme (ACE)-inhibitory activity (IC50: 74 μg/mL). A single oral administration of CH-3 led to a transient but significant decrease in the systolic blood pressure (SBP) of spontaneously hypertensive rats (SHRs), while daily oral administration of CH-3 for 28 consecutive days led to a lower rate of SBP increase. The CH-3 preparation was then fractionated and the αS2-casein-derived tripeptide Met-Lys-Pro (or MKP) was identified as a novel peptide with strong ACE-inhibitory activity (IC50 = 0.12 μg/mL, 0.3 μM). The MKP peptide constituted only 0.053% of CH-3 but its activity was accounted for 33% of the total ACE-inhibitory activity of CH-3. In addition, a single oral administration of MKP also led to a transient but significant decrease in the SBP of SHRs. 相似文献
14.
15.
目的:对合成二肽的ACE抑制活性进行系统地筛选,寻找具有高ACE抑制活性的二肽并研究其在动物体内的降血压作用。方法:利用可见光分光光度法对35种合成二肽的ACE抑制活性进行测定,并对具有高ACE抑制活性的二肽进一步测定其IC50值。选取ACE抑制效果最佳的二肽进行原发性高血压大鼠(SHR)降血压实验。实验采用灌胃方法分别以1、10、25、50、100 mg/kg的剂量溶于1 m L生理盐水进行给药,分别于给药后2 h和4 h测量大鼠血压变化。结果:研究发现大部分二肽都具有一定程度的ACE抑制活性,其中以氨基酸序列为半胱氨酸-丙氨酸(Cys-Ala,CA)和半胱氨酸-组氨酸(CysHis,CH)的二肽ACE抑制活性最高,其ACE抑制率分别达到84.38%和70.79%。经测定CA和CH的IC50值分别为23.22μmol/L和61.17μmol/L。SHR大鼠降血压实验表明CA在体内的降压效果显著。给药后4 h CA降压效果优于给药后2 h,给药后2 h CA降压效果与给药剂量呈较好的正相关性(R2>0.8)。结论:体外ACE抑制率测定及SHR大鼠降血压实验发现合成二肽CA具有较高的ACE抑制活性和较好的体内降血压效果,提示CA可以作为降血压保健食品的添加成分,值得进一步研究。 相似文献
16.
17.